DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 017364
NDA 017364 describes AQUATENSEN, which is a drug marketed by Medpointe Pharm Hlc and is included in one NDA. Additional details are available on the AQUATENSEN profile page.
The generic ingredient in AQUATENSEN is methyclothiazide. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the methyclothiazide profile page.
The generic ingredient in AQUATENSEN is methyclothiazide. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the methyclothiazide profile page.
Summary for 017364
| Tradename: | AQUATENSEN |
| Applicant: | Medpointe Pharm Hlc |
| Ingredient: | methyclothiazide |
| Patents: | 0 |
| Therapeutic Class: | Cardiovascular Agents |
| Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 017364
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 5MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
